See more : H.I.S. Co., Ltd. (HISJF) Income Statement Analysis – Financial Results
Complete financial analysis of Malachite Innovations, Inc. (MLCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Malachite Innovations, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Guangdong Mingzhu Group Co.,Ltd (600382.SS) Income Statement Analysis – Financial Results
- Advani Hotels & Resorts (India) Limited (ADVANIHOTR.BO) Income Statement Analysis – Financial Results
- Nova Vision Acquisition Corporation (NOVVW) Income Statement Analysis – Financial Results
- Aon plc (AON) Income Statement Analysis – Financial Results
- Elnet Technologies Limited (ELNET.BO) Income Statement Analysis – Financial Results
Malachite Innovations, Inc. (MLCT)
About Malachite Innovations, Inc.
Malachite Innovations, Inc., together with its subsidiaries, provides health and wellness products in the United States. It offers a portfolio of approximately 100 novel cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. The company also develops THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. In addition, it engages in identifying, investing in, and repositioning environmental situations with a focus on technological innovations and eco-friendly solutions. The company was formerly known as Vitality Biopharma, Inc. and changed its name to Malachite Innovations, Inc. in October 2021. Malachite Innovations, Inc. was incorporated in 2007 and is headquartered in Cleveland, Ohio.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 102.42K | 163.36K | 248.35K | 245.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 77.94K | 108.26K | 149.48K | 121.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 24.48K | 55.10K | 98.87K | 124.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 23.90% | 33.73% | 39.81% | 50.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 408.91K | 1.01M | 1.74M | 1.90M | 893.96K | 613.12K | 1.13M | 580.00K | 250.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.93M | 2.68M | 2.82M | 2.52M | 2.63M | 2.23M | 2.80M | 3.02M | 2.29M | 1.26M | 30.00K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.93M | 2.68M | 2.82M | 2.52M | 2.63M | 2.23M | 2.80M | 3.02M | 2.29M | 1.26M | 30.00K | 0.00 |
| Other Expenses | 0.00 | 1.00 | 1.37M | -8.00 | -3.00 | 1.00 | -3.00 | -2.41K | 8.97K | 2.34K | 606.00 | 26.04K |
| Operating Expenses | 2.34M | 3.69M | 5.94M | 4.42M | 3.53M | 2.84M | 3.93M | 3.60M | 2.55M | 1.26M | 30.61K | 26.04K |
| Cost & Expenses | 2.34M | 3.69M | 4.57M | 4.50M | 3.63M | 2.99M | 4.05M | 3.60M | 2.44M | 1.30M | 30.00K | 26.04K |
| Interest Income | 0.00 | 1.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 6.78K | 0.00 | 1.01K | 363.00 | 6.07K | 404.32K | 425.37K | 18.30K | 4.67K | 2.26K |
| Depreciation & Amortization | 1.46M | -672.65K | 12.27K | 87.75K | -1.75M | 2.60M | -237.15K | -145.68K | 125.37K | -1.70K | -5.33K | -1.84M |
| EBITDA | -880.85K | -4.37M | -20.12M | -4.31M | -5.22M | -140.97K | -4.04M | -3.75M | -2.31M | -1.30M | -35.33K | -28.29M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -4,207.19% | -3,194.40% | -56.76% | -1,645.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.34M | -3.69M | -4.57M | -4.40M | -3.47M | -2.74M | -3.81M | -3.60M | -2.44M | -1.30M | -30.00K | -26.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -4,292.86% | -2,125.09% | -1,103.99% | -1,548.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.46M | 60.48K | 117.33K | 87.75K | -1.75M | 2.60M | -243.21K | -550.00K | -300.00K | -20.00K | -10.00K | -1.84M |
| Income Before Tax | -880.85K | -3.63M | -4.45M | -4.31M | -5.22M | -141.33K | -4.05M | -4.15M | -2.74M | -1.32M | -40.00K | -28.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -4,207.19% | -3,195.02% | -56.91% | -1,647.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 733.13K | 124.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -880.85K | -4.37M | -20.14M | -4.31M | -5.22M | -141.33K | -4.05M | -4.15M | -2.74M | -1.32M | -40.00K | -28.29M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -4,207.19% | -3,195.02% | -56.91% | -1,647.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.09 | -0.61 | -0.19 | -0.38 | -0.02 | -0.57 | -0.69 | -0.51 | -0.26 | -0.01 | -3.85 |
| EPS Diluted | -0.02 | -0.09 | -0.61 | -0.19 | -0.38 | -0.02 | -0.57 | -0.69 | -0.51 | -0.26 | -0.01 | -3.85 |
| Weighted Avg Shares Out | 50.84M | 50.84M | 33.00M | 23.12M | 13.59M | 7.54M | 7.04M | 6.01M | 5.34M | 5.15M | 5.15M | 7.35M |
| Weighted Avg Shares Out (Dil) | 50.84M | 50.84M | 33.00M | 23.12M | 13.59M | 7.54M | 7.04M | 6.01M | 5.34M | 5.15M | 5.15M | 7.35M |
Malachite Innovations Changes its Name to Range Impact and Adopts New Ticker Symbol “RNGE”
Malachite Innovations Retains Investment Banking Firm to Assist in Implementation of Strategic Plan for Cannabinoid Drug Development Business
MALACHITE INNOVATIONS ANNOUNCES CLOSING OF $1.0 MILLION CAPITAL RAISE TO FUND FIRST ACQUISITION OF FORMER MINE LAND
MALACHITE INNOVATIONS ANNOUNCES CLOSING THE ACQUISITION OF ITS THIRD RECLAMATION BUSINESS IN WEST VIRGINIA
MALACHITE INNOVATIONS REPORTS SECOND QUARTER 2023 RESULTS
Source: https://incomestatements.info
Category: Stock Reports